Novo Nordisk says receives subpoena in the U.S.
COPENHAGEN (Reuters) - Denmark's Novo Nordisk said on Wednesday it had received a subpoena in the United States regarding potential criminal offences relating to marketing and promotion practices for a number of its products.
The world's biggest maker of insulin said in a statement that the office of the United States attorney for the District of Massachusetts had asked for documents relating to Novo Nordisk's diabetes products Novolog, Levemir and Victoza.
Novo said it would cooperate with the attorney in the investigation, and that the group was at this point unable to determine or predict the outcome of the matter, or assess the consequences.
It was not possible to predict how long the investigation would take, Novo Nordisk said in the statement.
- U.S. war veteran released by North Korea returns home |
- South Korea to make announcement on air zone; expansion is anticipated |
- Pro-Europe protesters gather for rally in Kiev
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- Obama defends interim Iran deal, seeks to assure Israel